Context Therapeutics Inc. CNTX
Set alert
0.20 USD +0.01 +6.82%
At close
0.21 +0.01 +3.91%
Pre-market · Nov 3, 7:18 AM ET
0.1886 Day range 0.2129
0.1886 52-week range 3.62
- YTD
- -86.26%
- 1 year
- -81.30%
- Open
- 0.19
- Prev close
- 0.1891
- Mkt cap
- 18.56M
- Vol
- 1.29M
- Avg vol
- 1.53M
- EPS
- -0.48
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1886
- High
- 0.2129
- Forward P/E
- -3.38
- Beta
- 2.25
- Short ratio
- 2.79
- Inst. own
- 76.40%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 1.79
- 200-d avg
- 1.86
- 1y target
- 7.70
6M chart
Signals (21)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 29, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| RSI: Oversold | Sep 11, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 4, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Oversold | Sep 1, 2026 | 2 months ago |
| RSI: Oversold | Aug 28, 2026 | 2 months ago |
| RSI: Oversold | Jul 17, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 1, 2026 | 4 months ago |
| RSI: Oversold | Jun 9, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
Newest 20 of 21.
Analyst view
Consensus: none
Price target (mean) 7.70 +3711.9% upside
Now 0.202
- Target (low)
- 4.50
- Target (mean)
- 7.70
- Target (high)
- 10.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy3
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.05 | -0.06 – -0.04 | -0.42 | +88.1% | 0 | 0.0% | 4 |
| Next quarter | -0.06 | -0.06 – -0.06 | -0.23 | +73.9% | 0 | 0.0% | 1 |
| Current year | -0.51 | -0.53 – -0.49 | -1.50 | +66.0% | 0 | 0.0% | 4 |
| Next year | -0.3025 | -0.37 – -0.24 | -0.51 | +40.7% | 0 | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | D. Boral Capital | Initiated | — | Buy |
| Sep 23, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 16, 2024 | Piper Sandler | Initiated | — | Overweight |
| May 9, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 9, 2024 | Maxim Group | Maintained | Buy | Buy |
| Mar 21, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 1, 2023 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Sep 11, 2023 | Maxim Group | Initiated | — | Buy |
| Jun 6, 2023 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Mar 23, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Feb 7, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 2, 2022 | HC Wainwright & Co. | Initiated | — | Buy |
| Jan 24, 2022 | ThinkEquity | Initiated | — | Buy |